Webinar Summary

• Explore how advanced 3D tumor models offer new in vitro capabilities
• Understand the importance of a highly annotated biorepository in developing new 3D tumor models
• Learn how novel 3D tumor models maintain the heterogeneity of the parent tumor
• Discover the applications of 3D tumor models in drug testing and evaluation

In vitro primary tumor models play a critical role in the development of new therapies. Historically, these in vitro models have relied on two-dimensional immortalized cell lines. While fundamental for early stages of drug development, such models do not translate during the later stages of drug evaluation. Recent advancements have introduced three-dimensional primary tumor models that more accurately replicate therapeutic responses. Their ease of use and scalability underlines the importance of these models to accelerate drug development pipelines. Realizing the full potential of these 3D systems requires access to highly characterized primary tumor samples.

Discovery Life Sciences (Discovery) leverages its highly annotated biorepository and a network of nearly 200 global clinical sites to enable the creation of advanced primary tumor models. The primary tumoroid models developed using Discovery's biorepository maintain the genomic and transcriptomic profiles of the parental tissue, and these systems are amendable to standard-of-care compound testing. Collectively, the integration of novel 3D tumor models, a robust, well-characterized biorepository, and comprehensive specialty lab services represents a significant advancement in cancer therapy development.